SLC5A2 and type 2 diabetes mellitus: In other areas within this field, models have already been developed to validate treatment selection algorithm for SGLT2 inhibitor and DPP‐4 inhibitor therapies in type 2 diabetes [39] However, the use of predictive models based on various clinical and socio‐economic variables for studying optimal glycaemic control in diabetes, assessed by isCGM glucose metrics, remains unexplored.